Glabridin reduces glucose uptake and energy supply in breast cancer cells by downregulating GLUT1 expression. It inhibits LDH activity and lactic acid production, blocks glycolysis, and lowers ATP levels, restricting cancer cell growth and proliferation. This evidence concerns the gene SLC2A1 and breast carcinoma.